Maggie L. Shaw

Dayna Johnson, PhD, MPH, MSW, MS, the Rollins School of Public Health at Emory University, discusses principal findings from the analysis of a 35-day sleep intervention study that utilized a mobile mindfulness app to manage stress and anxiety combined with healthy sleep practices.

It’s important to consider the social context, the social ecology, and the family environment when investigating behavioral sleep problems among children and adults, noted Arielle Williamson, PhD, DBSM, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine.

Judite Blanc, PhD, is lead author on the abstract, “Social Determinants of Sleep Disorders Among Multiethnic Americans in the NIH All of Us Research Program,” which was presented today at SLEEP 2023.

There are recent reports of a potential connection between atopic dermatitis in infants and young children and early exposure to antibiotics and laxatives; however, the totality of the evidence on this link remains lacking.

In this preview interview for SLEEP 2023, Rebecca Spencer, PhD, chair of the Associated Professional Sleep Societies Program Committee, highlights how bringing patients and clinicians together can inspire new ideas in sleep medicine.

This is the first study to investigate a potential connection between anthracycline chemotherapy and risk of heart failure (HF) in young adult cancer survivors.

Mitzi Joi Williams, MD, FAAN, medical director and CEO of Joi Life Wellness Neurology Clinic, discusses how underrepresentation of minority population patients in clinical trials became an issue and how education and raising awareness can begin to remedy it.

With surveys demonstrating that care disparities in atopic dermatitis (AD) may exist among pediatric patients with the chronic skin condition, investigators set out to determine AD’s prevalence by sociodemographic subgroup.

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.

The effect of education on survival outcomes was evaluated both overall and as it related to cardiovascular disease (CVD).

Jeff Hunnicutt, CEO of Highlands Oncology Group, discusses the difference between business intelligence and artificial intelligence (AI), including process implementation and data compilation.

Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health.

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Precision medicine starts with the patient-physician relationship, and this also involves an entire care team, emphasized Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Causes of heart failure (HF), medication usage, and HF-related hospitalization and death were investigated among patients from 40 countries and 4 economic levels.

Individuals living with heart failure in the United States are expected to top 8 million by 2030 vs the close to 6 million living with the disease between 2015 and 2018.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

Many adolescents and young adults (AYAs) with advanced heart disease prefer to be involved in decisions that have an impact on their medical care, but new survey results show there is a great need for educational communication efforts that involve their caregivers and clinicians.

The behavioral economic biases of 43 African American young adults aged 18 to 24 were evaluated on 4 fronts: present bias, information salience, overoptimism, and loss aversion.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.

Dupilumab treatment delivered at a specialized tertiary care center has great potential to improve patient clinical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP).

Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

Study investigators stress the importance of health care professionals familiarizing themselves with risk factors among a more diverse patient population.

This subanalysis of data from the VIRGO study encompassed 2979 patients who had an acute myocardial infarction (AMI), or heart attack, between ages 18 and 55 years; outcomes evaluated included all-cause and cause-specific acute events requiring hospitalization in the year after discharge for a heart attack.

It is likely that social determinants of health (SDOH) may affect the differences in outcomes from multiple sclerosis (MS) that we see among Black/African American and Hispanic/Latinx populations, absent more data on their genetics and ancestry, noted Mitzi Joi Williams, MD, FAAN.

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

The potential ethical implications for goals of care discussions between surrogate decision makers and health care providers concerning patients who reside in a state of cognitive motor dissociation were investigated in this new study from a team at Columbia University and New York Presbyterian Hospital.

Much more work needs to be done surrounding multiple sclerosis (MS) and treating pregnant patients safely, noted Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic.

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.